Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""ipilimumab"" wg kryterium: Temat


Tytuł :
Quantum binding energies of checkpoint CTLA-4 in complex with the immuno-oncological drug ipilimumab.
Autorzy :
Tavares ABMLA; Departamento de Bioquímica, Universidade Federal do Rio Grande do Norte, 59072-970, Natal-RN, Brazil. ínicas, Universidade Federal de Pernambuco, 50.670-901, Recife-PE, Brazil.
Albuquerque EL; Departamento de Biofísica e Farmacologia, Universidade Federal do Rio Grande do Norte, 59072-970, Natal-RN, Brazil. .
Pokaż więcej
Źródło :
Physical chemistry chemical physics : PCCP [Phys Chem Chem Phys] 2021 Jul 28; Vol. 23 (29), pp. 15620-15627.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Agents, Immunological/*chemistry
CTLA-4 Antigen/*antagonists & inhibitors
Immune Checkpoint Inhibitors/*chemistry
Ipilimumab/*chemistry
Amino Acid Sequence ; Antineoplastic Agents, Immunological/pharmacology ; CTLA-4 Antigen/chemistry ; Drug Screening Assays, Antitumor ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Ipilimumab/pharmacology ; Models, Molecular ; Protein Binding ; Protein Conformation ; Thermodynamics
Czasopismo naukowe
Tytuł :
Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.
Autorzy :
Alhalabi O; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hasanov E; Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wilson NR; Department of Internal Medicine, University of Texas Houston, McGovern Medical School, Houston, Texas, USA.
Araujo J; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wang J; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Campbell MT; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Goswami S; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Shah AY; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Gao J; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Msaouel P; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.; Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Tannir NM; Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2021 Jul 15; Vol. 149 (2), pp. 387-393. Date of Electronic Publication: 2021 Mar 24.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Carcinoma, Renal Cell/*drug therapy
Ipilimumab/*administration & dosage
Kidney Neoplasms/*drug therapy
Nivolumab/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Endpoint Determination ; Female ; Hospitalization ; Humans ; Ipilimumab/adverse effects ; Male ; Middle Aged ; Neoplasm Metastasis ; Nivolumab/adverse effects ; Retrospective Studies ; Survival Analysis ; Tertiary Care Centers ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Autorzy :
Pires da Silva I; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Westmead Hospital, Sydney, NSW, Australia; Blacktown Hospital, Sydney, NSW, Australia.
Ahmed T; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.
Reijers ILM; Netherlands Cancer Institute, Amsterdam, Netherlands.
Weppler AM; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.
Betof Warner A; Memorial Sloan Kettering Cancer Center, New York City, NY, USA.
Patrinely JR; Vanderbilt University Medical Center, Nashville, TN, USA.
Serra-Bellver P; The Christie NHS Foundation Trust, Manchester, UK.
Allayous C; AP-HP Dermatology, INSERM U976, Université de Paris, Saint Louis Hospital, Paris, France.
Mangana J; Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Nguyen K; Westmead Hospital, Sydney, NSW, Australia; Blacktown Hospital, Sydney, NSW, Australia.
Zimmer L; Department of Dermatology, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
Trojaniello C; Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Napoli, Italy.
Stout D; Alfred Hospital, Monash University, Melbourne, VIC, Australia.
Lyle M; Cairns Hospital, James Cook University, Cairns, QLD, Australia.
Klein O; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia.
Gerard CL; Oncology Department, Lausanne University Hospital, Lausanne, Switzerland.
Michielin O; Oncology Department, Lausanne University Hospital, Lausanne, Switzerland.
Haydon A; Alfred Hospital, Monash University, Melbourne, VIC, Australia.
Ascierto PA; Cancer Immunotherapy and Development Therapeutics Unit, Istituto Nazionale Tumori IRCCS Fondazione G Pascale, Napoli, Italy.
Carlino MS; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Westmead Hospital, Sydney, NSW, Australia; Blacktown Hospital, Sydney, NSW, Australia.
Lebbe C; AP-HP Dermatology, INSERM U976, Université de Paris, Saint Louis Hospital, Paris, France.
Lorigan P; The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, University of Manchester, Manchester, UK.
Johnson DB; Vanderbilt University Medical Center, Nashville, TN, USA.
Sandhu S; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia.
Lo SN; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia.
Blank CU; Netherlands Cancer Institute, Amsterdam, Netherlands.
Menzies AM; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia.
Long GV; Melanoma Institute Australia, University of Sydney, Sydney, NSW, Australia; Royal North Shore Hospital, Sydney, NSW, Australia; Mater Hospital, Sydney, NSW, Australia. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2021 Jun; Vol. 22 (6), pp. 836-847. Date of Electronic Publication: 2021 May 11.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Immune Checkpoint Inhibitors/*administration & dosage
Ipilimumab/*administration & dosage
Melanoma/*drug therapy
Programmed Cell Death 1 Receptor/*genetics
Aged ; Antibodies, Monoclonal, Humanized/administration & dosage ; Antibodies, Monoclonal, Humanized/adverse effects ; Cohort Studies ; Drug Resistance, Neoplasm/genetics ; Drug Resistance, Neoplasm/immunology ; Female ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Ipilimumab/adverse effects ; Male ; Melanoma/genetics ; Melanoma/immunology ; Melanoma/pathology ; Middle Aged ; Neoplasm Metastasis ; Nivolumab/administration & dosage ; Nivolumab/adverse effects ; Positron Emission Tomography Computed Tomography ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Progression-Free Survival ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Real-world, population-based cohort study of toxicity and resource utilization of second-line ipilimumab for metastatic melanoma in Ontario, Canada.
Autorzy :
Dai WF; Provincial Drug Reimbursement Program, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.; Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada.; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Beca J; Provincial Drug Reimbursement Program, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.; Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada.
Croxford R; ICES, Toronto, Ontario, Canada.
Isaranuwatchai W; Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada.; Centre for Excellence in Economic Analysis Research, St Michael's Hospital, Toronto, Ontario, Canada.; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
Menjak IB; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Petrella TM; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Mittmann N; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.; Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada.; Canadian Agency for Drugs and Technologies in Health, Canada.
Earle CC; ICES, Toronto, Ontario, Canada.; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Gavura S; Provincial Drug Reimbursement Program, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.
Mercer RE; Provincial Drug Reimbursement Program, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.; Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada.
Hanna TP; Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Canada.; Department of Oncology, Queen's University, Kingston, Ontario, Canada.; ICES, Queen's University, Kingston, Ontario, Canada.
Chan KKW; Provincial Drug Reimbursement Program, Ontario Health (Cancer Care Ontario), Toronto, Ontario, Canada.; Canadian Centre for Applied Research in Cancer Control, Toronto, Ontario, Canada.; Department of Medicine, University of Toronto, Toronto, Ontario, Canada.; Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
Pokaż więcej
Źródło :
International journal of cancer [Int J Cancer] 2021 Apr 15; Vol. 148 (8), pp. 1910-1918. Date of Electronic Publication: 2020 Nov 07.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Ipilimumab/*therapeutic use
Melanoma/*drug therapy
Population Surveillance/*methods
Skin Neoplasms/*drug therapy
Aged ; Female ; Gastrointestinal Diseases/chemically induced ; Heart Diseases/chemically induced ; Hospitalization/statistics & numerical data ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Immune Checkpoint Inhibitors/therapeutic use ; Ipilimumab/adverse effects ; Male ; Melanoma/mortality ; Melanoma/pathology ; Middle Aged ; Neoplasm Metastasis ; Ontario ; Retrospective Studies ; Skin Neoplasms/mortality ; Skin Neoplasms/pathology ; Survival Rate
Czasopismo naukowe
Tytuł :
Modest efficacy of nivolumab plus ipilimumab in patients with papillary renal cell carcinoma.
Autorzy :
Tachibana H; Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
Kondo T; Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
Ishihara H; Department of Urology, Tokyo Women's Medical University Tokyo, Tokyo, Japan.
Fukuda H; Department of Urology, Tokyo Women's Medical University Tokyo, Tokyo, Japan.
Yoshida K; Department of Urology, Tokyo Women's Medical University Tokyo, Tokyo, Japan.
Takagi T; Department of Urology, Tokyo Women's Medical University Tokyo, Tokyo, Japan.
Izuka J; Department of Urology, Tokyo Women's Medical University Tokyo, Tokyo, Japan.
Kobayashi H; Department of Urology, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
Tanabe K; Department of Urology, Tokyo Women's Medical University Tokyo, Tokyo, Japan.
Pokaż więcej
Źródło :
Japanese journal of clinical oncology [Jpn J Clin Oncol] 2021 Apr 01; Vol. 51 (4), pp. 646-653.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Carcinoma, Papillary/*drug therapy
Carcinoma, Renal Cell/*drug therapy
Ipilimumab/*therapeutic use
Kidney Neoplasms/*drug therapy
Nivolumab/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Renal Cell/pathology ; Disease Progression ; Female ; Humans ; Ipilimumab/adverse effects ; Kaplan-Meier Estimate ; Kidney Neoplasms/pathology ; Male ; Middle Aged ; Nivolumab/adverse effects ; Progression-Free Survival ; Proportional Hazards Models ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma.
Autorzy :
Mei Y; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Chen MM; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Liang H; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
Ma L; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. .; The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA. .
Pokaż więcej
Źródło :
Communications biology [Commun Biol] 2021 Mar 22; Vol. 4 (1), pp. 383. Date of Electronic Publication: 2021 Mar 22.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Gene Expression Profiling*
Antineoplastic Agents, Immunological/*therapeutic use
Biomarkers, Tumor/*genetics
Ipilimumab/*therapeutic use
Melanoma/*drug therapy
Melanoma/*genetics
Skin Neoplasms/*drug therapy
Skin Neoplasms/*genetics
Antigens, CD/genetics ; Antigens, Differentiation/genetics ; Antineoplastic Agents, Immunological/adverse effects ; Extracellular Matrix Proteins/genetics ; GPI-Linked Proteins/genetics ; Humans ; Ipilimumab/adverse effects ; Melanoma/immunology ; Melanoma/mortality ; Predictive Value of Tests ; Proteoglycans/genetics ; Risk Assessment ; Risk Factors ; Skin Neoplasms/immunology ; Skin Neoplasms/mortality ; Time Factors ; Transcriptome ; Treatment Outcome ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma.
Autorzy :
Rozeman EA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Hoefsmit EP; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Reijers ILM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Saw RPM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Surgery, Mater Hospital, Sydney, New South Wales, Australia.; Department of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Versluis JM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Krijgsman O; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
Dimitriadis P; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Sikorska K; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
van de Wiel BA; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Eriksson H; Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden.; Department of Oncology/Skin Cancer Center, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.
Gonzalez M; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.
Torres Acosta A; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Grijpink-Ongering LG; Department of Biometrics, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Shannon K; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Stretch J; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Surgery, Mater Hospital, Sydney, New South Wales, Australia.; Department of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Ch'ng S; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Surgery, Mater Hospital, Sydney, New South Wales, Australia.; Department of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Nieweg OE; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Surgery, Mater Hospital, Sydney, New South Wales, Australia.; Department of Surgery, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Mallo HA; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Adriaansz S; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Kerkhoven RM; Genomics Core Facility, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Cornelissen S; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Broeks A; Core Facility Molecular Pathology and Biobanking, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Klop WMC; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Zuur CL; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
van Houdt WJ; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Peeper DS; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
Spillane AJ; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Surgery, Mater Hospital, Sydney, New South Wales, Australia.; Breast and Melanoma Surgery Unit, Royal North Shore hospital, Sydney, New South Wales, Australia.
van Akkooi ACJ; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Scolyer RA; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital and New South Wales Health Pathology, Sydney, New South Wales, Australia.
Schumacher TNM; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Oncode Institute, Utrecht, the Netherlands.
Menzies AM; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.
Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Department of Medical Oncology, Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia.
Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. .; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands. .
Pokaż więcej
Źródło :
Nature medicine [Nat Med] 2021 Feb; Vol. 27 (2), pp. 256-263. Date of Electronic Publication: 2021 Feb 08.
Typ publikacji :
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Ipilimumab/*administration & dosage
Melanoma/*drug therapy
Nivolumab/*administration & dosage
Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/genetics ; B7-H1 Antigen/immunology ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/immunology ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/genetics ; CTLA-4 Antigen/immunology ; Disease-Free Survival ; Female ; Humans ; Immunotherapy/adverse effects ; Interferon-gamma/genetics ; Ipilimumab/adverse effects ; Male ; Melanoma/immunology ; Melanoma/pathology ; Middle Aged ; Mutation/genetics ; Neoadjuvant Therapy/adverse effects ; Neoplasm Staging ; Nivolumab/adverse effects ; Recurrence
Czasopismo naukowe
Tytuł :
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218).
Autorzy :
Hodi FS; Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Chapman PB; Medical Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Sznol M; Medical Oncology, Yale University School of Medicine and Smilow Cancer Center, Yale-New Haven Hospital, New Haven, Connecticut.
Lao CD; Dermatology, University of Michigan, Ann Arbor, Michigan.
Gonzalez R; Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA.
Smylie M; Medical Oncology and Clinical Research, Cross Cancer Institute, Edmonton, Alberta, Canada.
Daniels GA; Medical Oncology, UC San Diego Health - La Jolla, La Jolla, California.
Thompson JA; Phase 1 Clinical Trials Program, Seattle Cancer Care Alliance, Seattle, Washington.
Kudchadkar R; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia.
Sharfman W; Cutaneous Oncology, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy and Kimmel Cancer Center, Baltimore, Maryland.
Atkins M; Medical Oncology, Georgetown Lombardi Comprehensive Cancer Center, Washington DC.
Spigel DR; Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, Tennessee.
Pavlick A; Medical Oncology, Laura & Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, USA.
Monzon J; Medical Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Kim KB; Medical Oncology, California Pacific Medical Center Research Institute, San Francisco, California, USA.
Ernst S; Medical Oncology, London Health Sciences Centre, London, Ontario, Canada.
Khushalani NI; Cutaneous Oncology, H.Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
van Dijck W; Bristol Myers Squibb, Princeton, New Jersey, USA.
Lobo M; Bristol Myers Squibb, Princeton, New Jersey, USA.
Hogg D; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Pokaż więcej
Źródło :
Melanoma research [Melanoma Res] 2021 Feb 01; Vol. 31 (1), pp. 67-75.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Ipilimumab/*therapeutic use
Melanoma/*drug therapy
Nivolumab/*therapeutic use
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Ipilimumab/pharmacology ; Male ; Middle Aged ; Nivolumab/pharmacology ; North America ; United States ; Young Adult
Czasopismo naukowe
Tytuł :
Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis.
Autorzy :
Sasson SC; Translational Gastroenterology Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Zaunders JJ; Centre for Applied Medical Research, St Vincent's Hospital, Sydney, Australia.
Nahar K; Melanoma Institute Australia and The University of Sydney, Sydney, Australia.
Munier CML; The Kirby Institute, University of New South Wales, Sydney, Australia.
Fairfax BP; Department of Oncology, Churchill Hospital, Oxford, UK.; Department of Oncology, University of Oxford, Oxford, UK.; MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Olsson-Brown A; The Clatterbridge Cancer Centre NHS Foundation Trust and Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Jolly C; The Clatterbridge Cancer Centre NHS Foundation Trust and Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Read SA; Westmead Institute of Medical Research, Sydney, Australia.; Western Sydney University, Sydney, Australia.
Ahlenstiel G; Westmead Institute of Medical Research, Sydney, Australia.; Department of Gastroenterology, Blacktown Hospital, Sydney, Australia.
Palendira U; Discipline of Infectious Diseases and Immunology, The University of Sydney, Sydney, Australia.
Scolyer RA; Melanoma Institute Australia and The University of Sydney, Sydney, Australia.; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, Australia.
Carlino MS; Melanoma Institute Australia and The University of Sydney, Sydney, Australia.; Department of Medical Oncology, Westmead and Blacktown Hospitals, Sydney, Australia.
Payne MJ; Department of Oncology, Churchill Hospital, Oxford, UK.
Cheung VTF; Translational Gastroenterology Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Gupta T; Translational Gastroenterology Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK.; MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Klenerman P; Translational Gastroenterology Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Peter Medawar Building of Pathogen Research, University of Oxford, Oxford, UK.
Long GV; Melanoma Institute Australia and The University of Sydney, Sydney, Australia.; Department of Medical Oncology, Royal North Shore Hospital and Mater Hospitals, Sydney, Australia.
Brain O; Translational Gastroenterology Unit and Oxford Biomedical Research Centre, Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Department of Gastroenterology, John Radcliffe Hospital, Oxford, UK.
Menzies AM; Melanoma Institute Australia and The University of Sydney, Sydney, Australia.; Department of Medical Oncology, Royal North Shore Hospital and Mater Hospitals, Sydney, Australia.
Kelleher AD; Centre for Applied Medical Research, St Vincent's Hospital, Sydney, Australia.; The Kirby Institute, University of New South Wales, Sydney, Australia.
Pokaż więcej
Źródło :
Clinical and experimental immunology [Clin Exp Immunol] 2020 Dec; Vol. 202 (3), pp. 335-352. Date of Electronic Publication: 2020 Aug 19.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
CD8-Positive T-Lymphocytes*/immunology
CD8-Positive T-Lymphocytes*/pathology
Colitis*/chemically induced
Colitis*/immunology
Colitis*/pathology
Intestinal Mucosa*/immunology
Intestinal Mucosa*/pathology
Mucosal-Associated Invariant T Cells*/immunology
Mucosal-Associated Invariant T Cells*/pathology
T-Lymphocytes, Regulatory*/immunology
T-Lymphocytes, Regulatory*/pathology
Ipilimumab/*adverse effects
Nivolumab/*adverse effects
Adult ; Aged ; Female ; Flow Cytometry ; Humans ; Ipilimumab/administration & dosage ; Male ; Middle Aged ; Nivolumab/administration & dosage
Czasopismo naukowe
Tytuł :
Ipilimumab: an investigational immunotherapy for glioblastoma.
Autorzy :
Youssef G; MGH Cancer Center, Massachusetts General Hospital & Harvard Medical School , Boston, MA, USA.; Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital & Harvard Medical School , Boston, MA, USA.
Dietrich J; MGH Cancer Center, Massachusetts General Hospital & Harvard Medical School , Boston, MA, USA.; Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital & Harvard Medical School , Boston, MA, USA.
Pokaż więcej
Źródło :
Expert opinion on investigational drugs [Expert Opin Investig Drugs] 2020 Nov; Vol. 29 (11), pp. 1187-1193. Date of Electronic Publication: 2020 Oct 06.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Brain Neoplasms/*drug therapy
Glioblastoma/*drug therapy
Ipilimumab/*pharmacology
Animals ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/pharmacology ; Brain Neoplasms/immunology ; Brain Neoplasms/pathology ; CTLA-4 Antigen/immunology ; Glioblastoma/immunology ; Glioblastoma/pathology ; Humans ; Immunotherapy/methods ; Ipilimumab/administration & dosage ; Mice
Czasopismo naukowe
Tytuł :
Sweet's syndrome under ipilimumab therapy and a brief comparison of the cases in literature.
Autorzy :
Yaşar HA; Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
Akkus E; Department of Internal Medicine, Ankara University School of Medicine, Ankara, Turkey.
Heper A; Department of Pathology, Ankara University School of Medicine, Ankara, Turkey.
Akay BN; Department of Dermatology, Ankara University School of Medicine, Ankara, Turkey.
Urun Y; Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
Utkan G; Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
Pokaż więcej
Źródło :
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2020 Oct; Vol. 26 (7), pp. 1762-1764. Date of Electronic Publication: 2020 Feb 23.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Ipilimumab/*adverse effects
Melanoma/*drug therapy
Sweet Syndrome/*chemically induced
Biopsy ; CTLA-4 Antigen/antagonists & inhibitors ; Female ; Humans ; Ipilimumab/therapeutic use ; Middle Aged ; Prednisone/therapeutic use ; Skin Neoplasms/drug therapy
Czasopismo naukowe
Tytuł :
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).
Autorzy :
McKay RR; University of California San Diego, La Jolla, CA.
McGregor BA; Dana-Farber Cancer Institute, Boston, MA.
Xie W; Dana-Farber Cancer Institute, Boston, MA.
Braun DA; Dana-Farber Cancer Institute, Boston, MA.
Wei X; Dana-Farber Cancer Institute, Boston, MA.
Kyriakopoulos CE; University of Wisconsin, Carbone Cancer Center, Madison, WI.
Zakharia Y; University of Iowa Health Care, Holden Comprehensive Cancer Center, Iowa City, IA.
Maughan BL; University of Utah, Salt Lake City, UT.
Rose TL; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC.
Stadler WM; University of Chicago, Chicago, IL.
McDermott DF; Beth Israel Deaconess Medical Center, Boston, MA.
Harshman LC; Dana-Farber Cancer Institute, Boston, MA.
Choueiri TK; Dana-Farber Cancer Institute, Boston, MA.
Pokaż więcej
Źródło :
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2020 Dec 20; Vol. 38 (36), pp. 4240-4248. Date of Electronic Publication: 2020 Oct 27.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Renal Cell/*drug therapy
Immune Checkpoint Inhibitors/*therapeutic use
Ipilimumab/*therapeutic use
Nivolumab/*therapeutic use
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Female ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Ipilimumab/pharmacology ; Male ; Middle Aged ; Nivolumab/pharmacology
Czasopismo naukowe
Tytuł :
FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma.
Autorzy :
Wright K
Pokaż więcej
Źródło :
Oncology (Williston Park, N.Y.) [Oncology (Williston Park)] 2020 Nov 12; Vol. 34 (11), pp. 502-503.
Typ publikacji :
Journal Article
MeSH Terms :
Drug Approval*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Ipilimumab/*administration & dosage
Mesothelioma, Malignant/*drug therapy
Nivolumab/*administration & dosage
Humans ; Ipilimumab/adverse effects ; Mesothelioma, Malignant/mortality ; Nivolumab/adverse effects ; United States ; United States Food and Drug Administration
Czasopismo naukowe
Tytuł :
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Autorzy :
Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Naples, Italy. Electronic address: .
Del Vecchio M; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Mandalá M; Papa Giovanni XIII Hospital, Bergamo, Italy.
Gogas H; National and Kapodistrian University of Athens, Athens, Greece.
Arance AM; Hospital Clínic de Barcelona-IDIBAPS, Barcelona, Spain.
Dalle S; Hospices Civils de Lyon, Pierre Bénite, France.
Cowey CL; Texas Oncology-Baylor Charles A Sammons Cancer Center, Dallas, TX, USA.
Schenker M; Oncology Center Sf Nectarie, Craiova, Romania.
Grob JJ; Department of Dermatology, Aix-Marseille University, Hôpital de la Timone, Marseille, France.
Chiarion-Sileni V; Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Márquez-Rodas I; Department of Medical Oncology, General University Hospital Gregorio Marañón and CIBERONC, Madrid, Spain.
Butler MO; Department of Immuno-oncology, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Maio M; Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy.
Middleton MR; Department of Oncology, Churchill Hospital, Oxford, UK.
de la Cruz-Merino L; Department of Clinical Oncology, Hospital University Virgen Macarena, Seville, Spain.
Arenberger P; Department of Dermatology, Charles University Third Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
Atkinson V; Division of Cancer Services, Gallipoli Medical Research Foundation, University of Queensland, Brisbane, QLD, Australia.
Hill A; Department of Medical Oncology, Tasman Health Care, Southport, QLD, Australia.
Fecher LA; Department of Medical Oncology, Internal Medicine, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA.
Millward M; Department of Internal Medicine, University of Western Australia and Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Khushalani NI; Department of Cutaneous Oncology, H Lee Moffitt Cancer Center, Tampa, FL, USA.
Queirolo P; IEO European Institute of Oncology IRCCS, Milan, Italy.
Lobo M; Oncology Clinical Development, Bristol Myers Squibb, Princeton, NJ, USA.
de Pril V; Department of Global Regulatory and Safety Sciences, Bristol Myers Squibb, Princeton, NJ, USA.
Loffredo J; Clinical Biomarkers, Bristol Myers Squibb, Princeton, NJ, USA.
Larkin J; Department of Medical Oncology, The Royal Marsden NHS Foundation Trust, London, UK.
Weber J; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
Pokaż więcej
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 Nov; Vol. 21 (11), pp. 1465-1477. Date of Electronic Publication: 2020 Sep 19.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug-Related Side Effects and Adverse Reactions/*pathology
Ipilimumab/*administration & dosage
Melanoma/*drug therapy
Nivolumab/*administration & dosage
Aged ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/genetics ; Disease-Free Survival ; Double-Blind Method ; Drug-Related Side Effects and Adverse Reactions/classification ; Female ; Humans ; Ipilimumab/adverse effects ; Male ; Melanoma/genetics ; Melanoma/pathology ; Melanoma/surgery ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/surgery ; Neoplasm Staging ; Nivolumab/adverse effects ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Quantum biochemistry in cancer immunotherapy: New insights about CTLA-4/ipilimumab and design of ipilimumab-derived peptides with high potential in cancer treatment.
Autorzy :
Amaral JL; Department of Biochemistry and Molecular Biology, Federal University of Ceará, Fortaleza, Ceará, CEP 60.440-554, Brazil; Department of Physics, Federal University of Ceará, Fortaleza, Ceará, CEP 60.440-970, Brazil. Electronic address: .
Santos SJM; Federal Institute of Education, Science and Technology of Rio Grande Do Sul, Feliz, Rio Grande Do Sul, CEP 95770-000, Brazil.
Souza PFN; Department of Biochemistry and Molecular Biology, Federal University of Ceará, Fortaleza, Ceará, CEP 60.440-554, Brazil.
de Morais PA; Federal Institute of Education, Science and Technology of Ceará, Horizonte, Ceará, CEP 62.884-105, Brazil.
Maia FF Jr; Department of Nature Sciences, Mathematics and Statistics, Federal Rural University of Semi-arid, Mossoró, Rio Grande Do Norte, CEP 59.625-900, Brazil.
Carvalho HF; Department of Structural and Functional Biology, Institute of Biology, State University of Campinas, Campinas, SP, CEP 13.083-862, Brazil.
Freire VN; Department of Physics, Federal University of Ceará, Fortaleza, Ceará, CEP 60.440-970, Brazil.
Pokaż więcej
Źródło :
Molecular immunology [Mol Immunol] 2020 Nov; Vol. 127, pp. 203-211. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Drug Design*
Immunotherapy*
Antineoplastic Agents/*therapeutic use
CTLA-4 Antigen/*immunology
Ipilimumab/*therapeutic use
Neoplasms/*immunology
Neoplasms/*therapy
Peptides/*therapeutic use
CTLA-4 Antigen/chemistry ; Electricity ; Humans ; Ipilimumab/chemistry ; Molecular Dynamics Simulation ; Peptides/chemistry ; Protein Binding ; Proteolysis ; Thermodynamics
Czasopismo naukowe
Tytuł :
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
Autorzy :
Schoenfeld JD; Brigham and Women's Hospital, Boston, Massachusetts.; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Hanna GJ; Brigham and Women's Hospital, Boston, Massachusetts.; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Jo VY; Brigham and Women's Hospital, Boston, Massachusetts.
Rawal B; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; PRA Health Sciences, Boston, Massachusetts.
Chen YH; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Catalano PS; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Lako A; Brigham and Women's Hospital, Boston, Massachusetts.; Bristol-Myers Squibb, Boston, Massachusetts.
Ciantra Z; Brigham and Women's Hospital, Boston, Massachusetts.
Weirather JL; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Criscitiello S; Brigham and Women's Hospital, Boston, Massachusetts.; Beth-Israel Deaconess Medical Center, Boston, Massachusetts.
Luoma A; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Chau N; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; British Columbia Cancer, Vancouver, Canada.
Lorch J; Brigham and Women's Hospital, Boston, Massachusetts.; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Kass JI; Brigham and Women's Hospital, Boston, Massachusetts.; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Annino D; Brigham and Women's Hospital, Boston, Massachusetts.; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Goguen L; Brigham and Women's Hospital, Boston, Massachusetts.; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Desai A; Beth-Israel Deaconess Medical Center, Boston, Massachusetts.
Ross B; Brigham and Women's Hospital, Boston, Massachusetts.; McGill Medical School, Montreal, Canada.
Shah HJ; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Jacene HA; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Margalit DN; Brigham and Women's Hospital, Boston, Massachusetts.; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Tishler RB; Brigham and Women's Hospital, Boston, Massachusetts.; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Wucherpfennig KW; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Rodig SJ; Brigham and Women's Hospital, Boston, Massachusetts.; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Uppaluri R; Brigham and Women's Hospital, Boston, Massachusetts.; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Haddad RI; Brigham and Women's Hospital, Boston, Massachusetts.; Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
Pokaż więcej
Źródło :
JAMA oncology [JAMA Oncol] 2020 Oct 01; Vol. 6 (10), pp. 1563-1570.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Ipilimumab/*administration & dosage
Mouth Neoplasms/*drug therapy
Nivolumab/*therapeutic use
Squamous Cell Carcinoma of Head and Neck/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Female ; Humans ; Ipilimumab/adverse effects ; Male ; Middle Aged ; Mouth Neoplasms/mortality ; Mouth Neoplasms/pathology ; Neoadjuvant Therapy ; Nivolumab/administration & dosage ; Nivolumab/adverse effects ; Positron Emission Tomography Computed Tomography ; Squamous Cell Carcinoma of Head and Neck/mortality ; Squamous Cell Carcinoma of Head and Neck/pathology
Czasopismo naukowe
Tytuł :
Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US.
Autorzy :
Watson TR; Institute for Technology Assessment, Massachusetts General Hospital, Boston.
Gao X; Massachusetts General Hospital Cancer Center, Boston.; Harvard Medical School, Boston, Massachusetts.
Reynolds KL; Massachusetts General Hospital Cancer Center, Boston.; Harvard Medical School, Boston, Massachusetts.
Kong CY; Institute for Technology Assessment, Massachusetts General Hospital, Boston.; Harvard Medical School, Boston, Massachusetts.
Pokaż więcej
Źródło :
JAMA network open [JAMA Netw Open] 2020 Oct 01; Vol. 3 (10), pp. e2016144. Date of Electronic Publication: 2020 Oct 01.
Typ publikacji :
Comparative Study; Journal Article
MeSH Terms :
Antibodies, Monoclonal, Humanized/*economics
Axitinib/*economics
Carcinoma, Renal Cell/*drug therapy
Carcinoma, Renal Cell/*economics
Ipilimumab/*economics
Nivolumab/*economics
Sunitinib/*economics
Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents, Immunological/economics ; Antineoplastic Agents, Immunological/therapeutic use ; Axitinib/therapeutic use ; Cost-Benefit Analysis/statistics & numerical data ; Female ; Humans ; Ipilimumab/therapeutic use ; Kidney Neoplasms/drug therapy ; Kidney Neoplasms/economics ; Male ; Middle Aged ; Nivolumab/therapeutic use ; Sunitinib/therapeutic use ; United States/epidemiology
Czasopismo naukowe
Tytuł :
Nivolumab monotherapy or combination therapy with ipilimumab for lung cancer: a systemic review and meta-analysis.
Autorzy :
Jiang, Huihui (AUTHOR)
Xu, Aiqun (AUTHOR)
Xia, Wanli (AUTHOR)
Xia, Xingyuan (AUTHOR)
Li, Pulin (AUTHOR)
Zhang, Binbin (AUTHOR)
Zhu, Ke (AUTHOR)
Zhou, Sijing (AUTHOR)
Wang, Ran (AUTHOR)
Pokaż więcej
Źródło :
Cancer Cell International. 8/14/2021, Vol. 21 Issue 1, p1-12. 12p.
Czasopismo naukowe
Tytuł :
Successful treatment of BRAF/MEK inhibitor-resistant advanced cutaneous melanoma with nivolumab plus ipilimumab combination therapy followed by intensity-modulated radiotherapy.
Autorzy :
Okuma T; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Furudate S; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kambayashi Y; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Hashimoto A; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Aiba S; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Fujimura T; Department of Dermatology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Pokaż więcej
Źródło :
The Journal of dermatology [J Dermatol] 2021 Sep; Vol. 48 (9), pp. 1419-1422. Date of Electronic Publication: 2021 May 18.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Melanoma*/drug therapy
Melanoma*/genetics
Radiotherapy, Intensity-Modulated*
Skin Neoplasms*/drug therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; CD8-Positive T-Lymphocytes ; Humans ; Ipilimumab/therapeutic use ; Mitogen-Activated Protein Kinase Kinases ; Nivolumab/therapeutic use ; Proto-Oncogene Proteins B-raf/genetics ; Tumor Microenvironment
Czasopismo naukowe
Tytuł :
Spontaneous and Immune Checkpoint Inhibitor-Induced Autoimmune Diseases: Analysis of Temporal Information by Using the Japanese Adverse Drug Event Report Database.
Autorzy :
Ogawa K; Laboratory of Regulatory Science, College of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, Shiga, 525-8577, Japan.
Kozuka Y; Laboratory of Regulatory Science, College of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, Shiga, 525-8577, Japan.
Uno H; Laboratory of Regulatory Science, College of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, Shiga, 525-8577, Japan.
Utsumi K; Laboratory of Regulatory Science, College of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, Shiga, 525-8577, Japan.
Noyori O; Laboratory of Immunology and Microbiology, College of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, Shiga, 525-8577 , Japan.
Hosoki R; Laboratory of Regulatory Science, College of Pharmaceutical Sciences, Ritsumeikan University, 1-1-1 Noji-Higashi, Kusatsu, Shiga, 525-8577, Japan. .
Pokaż więcej
Źródło :
Clinical drug investigation [Clin Drug Investig] 2021 Jul; Vol. 41 (7), pp. 615-627. Date of Electronic Publication: 2021 Jun 10.
Typ publikacji :
Journal Article
MeSH Terms :
Autoimmune Diseases/*diagnosis
Immune Checkpoint Inhibitors/*adverse effects
Autoimmune Diseases/chemically induced ; CTLA-4 Antigen/antagonists & inhibitors ; CTLA-4 Antigen/metabolism ; Cluster Analysis ; Databases, Factual ; Diabetes Mellitus, Type 1/drug therapy ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Ipilimumab/adverse effects ; Ipilimumab/therapeutic use ; Japan ; Myasthenia Gravis/drug therapy ; Odds Ratio ; Programmed Cell Death 1 Receptor/antagonists & inhibitors ; Programmed Cell Death 1 Receptor/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies